The impact of the geopolitical disruption is starting to tell on global supply chains for medicines and key chemicals for the pharmaceutical industry.
Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.
A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
Editor's Picks
